Physician profile
Jonathan D Meadows
NPI 1033787536
$1,956.77
in general payments reported to CMS, 2019-2025
14 companies · $720 in 2025
The $720 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.39 · 2022: $203 · 2023: $463 · 2024: $551 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,708.70 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $401.14 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $337.76 | 2022-2025 | |
| Novo Nordisk INC | $230.80 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $194.40 | 2021-2025 | |
| Pfizer INC. | $191.46 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $183.63 | 2023-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $135.10 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $66.79 | 2023-2025 | Otezla, Repatha, Repatha |
| Kowa Pharmaceuticals America, INC. | $59.66 | 2022-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.52 | 2023-2024 | Jardiance |
| Currax Pharmaceuticals LLC | $40.16 | 2023-2025 | Nexletol, Contrave |
| Hikma Pharmaceuticals USA | $31.14 | 2024-2025 | Ryaltris |
| Dexcom, INC. | $19.81 | 2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $19.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.